Pegacaristim

Drug Profile

Pegacaristim

Alternative Names: KRN 9000; Megakaryocyte growth and development factor; MGDF; PEG thrombopoietin - Kirin-Amgen; PEG-MGDF; PEG-rHuMGDF; PEG-rMGDF; Pegylated megakaryocyte growth and development factor; Pegylated recombinant megakaryocyte growth and development factor; Polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor; Thrombopoietin - Kirin-Amgen

Latest Information Update: 29 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen; Kirin Brewery; ZymoGenetics
  • Developer Amgen; Kirin Holdings Company; ZymoGenetics
  • Class Antineoplastics; Growth factors
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; Thrombocytopenia

Most Recent Events

  • 29 Feb 2008 Discontinued - Phase-II for Thrombocytopenia (Chemotherapy-induced) in Japan (unspecified route)
  • 13 Jan 2005 Discontinued - Clinical-Phase-Unknown for Thrombocytopenia (Chemotherapy-induced) in Europe (SC)
  • 13 Jan 2005 No development reported - Phase-II for Thrombocytopenia (Chemotherapy-induced) in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top